Cingulate Inc. Common Stock

CINGNASDAQ • USD
ThemeBiotech - Drug Development›Neuroscience & CNS
4.80 USD
↘ 0.08 (1.64%)AT CLOSE (11:59 AM EDT)
4.85
↗ 0.05 (0.94%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
4.85
↗ 0.05 (0.94%)
🔴Market: CLOSED
Open?$4.78
High?$5.15
Low?$4.72
Prev. Close?$4.88
Volume?611.4K
Avg. Volume?748.2K
VWAP?$4.90
Rel. Volume?0.82x
Bid / Ask
Bid?$4.05 × 100
Ask?$5.61 × 100
Spread?$1.56
Midpoint?$4.83
Valuation & Ratios
Market Cap?65.7M
Shares Out?13.5M
Float?10.5M
Float %?95.7%
P/E Ratio?N/A
P/B Ratio?3.48
EPS?-$2.06
Dividend?0.00%
Ex-Dividend?N/A

CING is currently priced at $4.81. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, CING trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Jun 4, 2026.

News
Profile
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Themes
Biotech - Drug Development›Neuroscience & CNS
Employees
14
Market Cap
65.7M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.cingulate.com
Listed
2021-12-08
Address
1901 W. 47TH PLACE
KANSAS CITY, KS 66205
Phone: (913) 942-2300
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
23
Short Sent.?
26
Piotroski F-Score?0/9Weak
Altman Z-Score?-5.06Distress
Confidence?60%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?15.07%High
Short Interest?1.6M
Days to Cover?3.6
Free Float10.5M
Avg Daily Volume442.6K
Settlement Date2026-05-15
Financial Health
Current Ratio?2.55Strong
Quick Ratio?2.55Strong
Cash Ratio?2.36Strong
Debt/Equity?0.33Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
49
3.48FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.9CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-146.9%WEAK▾
ROA?
S&P
3
-89.8%WEAK▾
Cash Flow & Enterprise
FCF?$-19773181
Enterprise Value?$46.0M
Fundamentals ratios updated end of day
MarketsMoversWatchlist